Boehringer Ingelheim’s SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Foundation. The Prix Galien USA Award was presented last night in New York.
Prix Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. In 2022 the U.S. Food and Drug Administration approved spesolimab as a treatment option for GPP flares in adults and the European Medicine Agency granted a conditional market authorization as first-in-class treatment option for GPP flares in adults.
“Being nominated and winning the Prix Galien for SPEVIGO® is a testament to the exceptional work of our research and development teams to bring the first targeted and highly effective immunomodulatory biologic to people living with generalized pustular psoriasis (GPP). We are honored to be recognized among the best of the best in the pharmaceutical industry,” said Michel Pairet, member of the Board of Managing Directors and Head of the Innovation Unit. “Our scientists have achieved deep biological insights into GPP uncovering the key pathway driving the disease, and based on this developed the first specific treatment for GPP flares.”
“SPEVIGO® winning the Prix Galien is a great honor! It reinforces our values and mission to bring innovative treatments better and faster to the people that need it most, especially with rare diseases like GPP. GPP flares may appear suddenly, intensify quickly and can be life-threatening if left untreated, leaving those affected and their loved ones feeling anxious and uncertain about their future. We are humbled by the positive impact SPEVIGO® has had on GPP patients across the world, and take this recognition as a driver to continue our pursuit for their continued benefit,” said Carinne Brouillon, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim.
"We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry,” said Bruno Cohen, Chairman of The Galien Foundation.
Late-breaking data from the EFFISAYIL™ 2 trial presented in 2023 showed that spesolimab prevents GPP flares. It significantly reduced the risk of occurrence of GPP flares by 84% over 48 weeks compared to placebo. Furthermore, the trial with 123 patients demonstrated no flares after Week 4 of spesolimab treatment in the high dose group1. Boehringer Ingelheim has submitted spesolimab for regulatory approval based on these data to, not only provide patients with a specific treatment for GPP flares but moving forward also for the prevention of flares.
Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
References
1.Morita et al. Lancet. 2023 Sep 19:S0140-6736(23)01378-8.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231027763389/en/
Contact information
Harro ten Wolde
Phone: +49 151 61901069
Email: press@boehringer-ingelheim.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kenvue to Participate in the Morgan Stanley Global Consumer & Retail Conference on December 6, 202328.11.2023 14:00:00 CET | Press release
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Morgan Stanley’s Global Consumer & Retail Conference, in New York. Chief Executive Officer and Director, Thibaut Mongon, and Chief Financial Officer, Paul Ruh, will participate in a fireside chat on Wednesday, December 6, 2023 at 11:45 a.m. Eastern Time. A live webcast of the session will be available at https://investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power
Bacardi Gifting Celebrates Sustainability Landmark28.11.2023 14:00:00 CET | Press release
Family-owned Bacardi has announced that it is not only cutting single-use plastic from its gift packs, it will also now reduce the number of cardboard gift boxes for some of its iconic brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128855110/en/ The new limited-edition label for Bacardi-owned BOMBAY SAPPHIRE eliminates the need for a gift pack. The striking design was inspired by the gin brand’s 100% sustainably sourced botanicals. (Photo: Business Wire) Four years ago, Bacardi set itself the ambitious goal of removing 100% of the single-use plastic from its gifting range by the end of 2023. Thanks to innovative new designs, the company has successfully removed almost 275 tons of single-use plastic used annually. “We are incredibly proud of what we have achieved to date but we want to go one step further,” said Rodolfo Nervi, Vice President Safety, Quality and Sustainability for Bacardi. “We don’t want to just red
New Research: 97% of U.S. CIOs Identify Cybersecurity as a Current Major Threat to Their Organization28.11.2023 14:00:00 CET | Press release
According to new research released by Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and SmartOut of Bandmanagement solutions, a staggering 97% of U.S.-based CIOs surveyed expressed serious concerns about at least one cybersecurity threat. This comprehensive survey encompassed responses from 502 CIOs and 510 network engineers in the U.S., U.K., France, Germany, and Australia. The primary cybersecurity concerns highlighted in the research included malware (42%), spam and phishing (34%), social engineering (31%), and insider threats (30%). Remarkably, malware also emerged as a significant threat for 42% of the surveyed network engineers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128568826/en/ New Research: 97% of U.S. CIOs Identify Cybersecurity as a Current Major Threat to Their Organization (Photo: Business Wire) While only 23% of U.S. CIOs reported distributed denial-of-se
New VCMI Guidance Opens Door for Corporate Carbon Credit Claims28.11.2023 11:36:00 CET | Press release
The Voluntary Carbon Markets Integrity Initiative (VCMI) has today released additional guidance for its Claims Code of Practice (Claims Code), enabling companies to make claims about their use of high-quality carbon credits. This guidance includes a Monitoring, Reporting and Assurance (MRA) Framework, a brand and associated mark for making ‘Carbon Integrity' Claims, and a beta version of an additional claim. Using the MRA framework and the ‘Carbon Integrity’ Claims branding, companies can now make Silver, Gold or Platinum Claims as outlined in the original Claims Code of Practice released in June. This means these companies can now make claims using high-quality carbon credits, directing finance to initiatives that mitigate climate change, and demonstrating that they are going above and beyond science-aligned emissions cuts. VCMI has also launched the beta version of a new claim – called the ‘Scope 3 Flexibility’ Claim - as a practical step to accelerate corporate climate action. Once
inDrive welcomes Stephen Kruger as Chief Technology and Product Officer28.11.2023 10:00:00 CET | Press release
inDrive, a global mobility and urban services platform, announces the appointment of Stephen Kruger as its Chief Technology and Product Officer. Stephen will be responsible for implementing inDrive’s technology and product development strategies as the company continues to expand into new geographies and business verticals. inDrive has built out its platform with geography-specific freight and courier offerings, as well as handyman services, in addition to its core ride-hailing business. The combined technology and product team is tasked with continuing to scale inDrive’s platform, implementing new product features to support growth and further diversification of the business. Welcoming Stephen to the team, inDrive founder and CEO Arsen Tomsky said: "Stephen's remarkable background in technology leadership aligns seamlessly with our vision for inDrive's future. His proven ability to drive organizational change and innovation will undoubtedly strengthen our position in the industry whil